Holen Sie sich die Stockscreener-App
77.16
2.28%
-1.80
Handel nachbörslich:
77.16
Schlusskurs vom Vortag:
$78.96
Offen:
$79.03
24-Stunden-Volumen:
1.01M
Relative Volume:
0.88
Marktkapitalisierung:
$3.27B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.78M
KGV:
-28.79
EPS:
-2.68
Netto-Cashflow:
$-53.91M
1W Leistung:
+8.72%
1M Leistung:
+56.19%
6M Leistung:
+592.64%
1J Leistung:
+397.81%
1-Tages-Spanne:
$76.42
$79.97
1-Wochen-Bereich:
$71.50
$80.13
52-Wochen-Spanne:
$7.575
$83.00
Celcuity Inc Stock (CELC) Company Profile
Firmenname
Celcuity Inc
Sektor
Branche
Telefon
763-392-0767
Adresse
16305 36TH AVENUE N, MINNEAPOLIS, MN
Vergleichen Sie CELC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
77.16 | 3.35B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Eingeleitet | Guggenheim | Buy |
| 2025-07-01 | Fortgesetzt | Stifel | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-22 | Eingeleitet | Stifel | Buy |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-07 | Eingeleitet | Jefferies | Buy |
| 2021-07-29 | Eingeleitet | Cowen | Outperform |
| 2021-07-27 | Eingeleitet | Needham | Buy |
| 2021-01-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-11 | Fortgesetzt | Craig Hallum | Buy |
| 2018-11-20 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Celcuity Inc Aktie (CELC) Neueste Nachrichten
How to track smart money flows in Celcuity Inc.2025 Analyst Calls & Detailed Earnings Play Strategies - newser.com
What drives Celcuity Inc stock priceTechnical Analysis Insights & Build Diversified Portfolios With Ease - earlytimes.in
Sector ETF performance correlation with Celcuity Inc.Gap Up & Safe Capital Allocation Plans - newser.com
Will Celcuity Inc. stock benefit from AI adoption2025 Volatility Report & Precise Swing Trade Entry Alerts - newser.com
Price action breakdown for Celcuity Inc.Weekly Trend Report & AI Based Trade Execution Alerts - newser.com
Why analysts upgrade Celcuity Inc. stockQuarterly Market Summary & Daily Oversold Stock Bounce Ideas - newser.com
What institutional flow reveals about Celcuity Inc.Market Sentiment Summary & Fast Moving Stock Trade Plans - newser.com
Candlestick signals on Celcuity Inc. stock todayJuly 2025 Institutional & Expert Approved Trade Ideas - newser.com
How buybacks impact Celcuity Inc. stock valueTrade Signal Summary & Safe Entry Trade Signal Reports - newser.com
Celcuity (CELC) Is Up 11.9% After Revealing Efficacy of Gedatolisib in ESMO Trial Results - simplywall.st
Celcuity : Corporate Presentation (Celcuity Investor Presentation V.7.1.2 Final) - MarketScreener
Celcuity (CELC) Price Target Increased by 10.74% to 84.15 - Nasdaq
When is the best time to exit Celcuity Inc.Oil Prices & Reliable Entry Point Trade Alerts - newser.com
How currency fluctuations impact Celcuity Inc. stockEarnings Beat & Technical Buy Zone Confirmation - newser.com
What analysts say about Celcuity Inc stockVolatility Trading Techniques & Grow Steadily With Our Wealth Roadmap - earlytimes.in
Published on: 2025-10-27 20:00:39 - newser.com
Is It Too Late to Buy Celcuity Stock? - StocksToTrade
Celcuity Inc.’s Promising Phase 3 Breast Cancer Study: A Market Game-Changer? - TipRanks
Celcuity’s Phase 3 Breast Cancer Study: A Potential Game-Changer? - TipRanks
Celcuity Shares Surge Amid Promising Cancer Study - TipRanks
Celcuity Inc.’s Promising Study on mCRPC Treatment: Key Insights for Investors - TipRanks
Finanzdaten der Celcuity Inc-Aktie (CELC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):